Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-07-06
2011-11-29
Anderson, Rebecca (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S204000
Reexamination Certificate
active
08067449
ABSTRACT:
The present application provides for a compound of Formula I, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, compositions containing such compounds, therapeutic methods that include the administration of such compounds, and therapeutic methods and include the administration of such compounds with at least one additional therapeutic agent.
REFERENCES:
patent: 5142056 (1992-08-01), Kempe et al.
patent: 5354866 (1994-10-01), Kempf et al.
patent: 5362912 (1994-11-01), Sowin et al.
patent: 5539122 (1996-07-01), Kempf et al.
patent: 5541206 (1996-07-01), Kempf et al.
patent: 5552558 (1996-09-01), Kempf et al.
patent: 5565418 (1996-10-01), Kempf et al.
patent: 5580984 (1996-12-01), Kempf et al.
patent: 5583232 (1996-12-01), Kempf et al.
patent: 5583233 (1996-12-01), Kempf et al.
patent: 5591860 (1997-01-01), Kempf et al.
patent: 5597927 (1997-01-01), Kempf et al.
patent: 5597928 (1997-01-01), Kempf et al.
patent: 5608072 (1997-03-01), Kempf et al.
patent: 5616720 (1997-04-01), Kempf et al.
patent: 5625072 (1997-04-01), Kempf et al.
patent: 5635523 (1997-06-01), Kempf et al.
patent: 5659044 (1997-08-01), Kempf et al.
patent: 5659045 (1997-08-01), Kempf et al.
patent: 5674882 (1997-10-01), Kempf et al.
patent: 5679797 (1997-10-01), Kempf et al.
patent: 5696270 (1997-12-01), Kempf et al.
patent: 5763464 (1998-06-01), Randad et al.
patent: 5892052 (1999-04-01), Kempf et al.
patent: 6448245 (2002-09-01), DePetrillo et al.
patent: 2002/0115665 (2002-08-01), DePetrillo et al.
patent: 2003/0191319 (2003-10-01), Vazquez et al.
patent: 2004/0127689 (2004-07-01), Sigler et al.
patent: 2006/0199851 (2006-09-01), Kempf et al.
patent: 2008/0108617 (2008-05-01), Desai et al.
patent: 2008/0207620 (2008-08-01), Desai et al.
patent: 2009/0181902 (2009-07-01), Desai et al.
patent: 0428849 (1991-05-01), None
patent: 486948 (1992-05-01), None
patent: 0674513 (1995-10-01), None
patent: 1090914 (2001-04-01), None
patent: 1183026 (2002-03-01), None
patent: 1302468 (2003-04-01), None
patent: 2773994 (1999-07-01), None
patent: WO-94/14436 (1994-07-01), None
patent: WO-97/01349 (1997-01-01), None
patent: WO-01/25240 (2001-04-01), None
patent: WO-2005/111006 (2005-11-01), None
patent: WO-2008/010921 (2008-01-01), None
Morissette et al. “High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids.” Advanced Drug Delivery Reviews 2004, 56, 275-300.
Souillac, et al., Characterization of Delivery Systems, Differential Scanning Calorimetry, pp. 217-218 (in Encyclopedia of Controlled Drug Delivery, 1999, John Wiley & Sons, pp. 212-227).
Vippagunta, Sudha R. “Crystalline Solids.” Advanced Drug Delivery Reviews 48(2001): 3-26.
Gurjar et al. (1997) “Synthesis of Novel C2-symmetric and Pseudo C2-symmetric Based Diols, Epoxides and Dideoxy Derivatives of HIV Protease Inhibitors,”Tetrahedron53(13):4769-4778.
Kempf et al. (1998) “Discovery of Ritonavir, a Patent Inhibitor of HIV Protease with High Oral Bioavailability and Clinical Efficacy,”J. Med. Chem.41:602-617.
Molla et al. (1996) “Ordered Accumulation of Mutations in HIV Protease Confers Resistance to Ritonavir,”Nature Medicine2:(7):760-766.
Bai, J. et al. (2004) “Use of Classification Regression Tree in Predicting Oral Absorption in Humans,”J. Chem Inf. Comput. Sci44:2061-2069.
Frecer, V. et al. (2005) “Structure Based Design of Inhibitors of Aspartic Protease of HIV-1,”Letters in Drug Design&Discovery2:638-646.
Kempf,D. et al. (1997) “Lack of Stereospecificity in the Binding of the P2 Amino Acid of Ritonavir to HIV Protease,”Bioorganic&Medicinal Chemistry Letters7(6):699-704.
Mekapati, S.B. et al. (2001) “Quantitative Structure-Activity Relationship of some HIV-1 Protease Inhibitors: A Fujita-Ban Type Analysis,”J. Enzyme Inhibition16:185-197.
Nair, A. et al. (1998) “A Computational Study of the Resistance of HIV-1 Aspartic Protease to the Inhibitors ABT-538 and VX-478 and Design of New Analogues,”Biochemical and Biophysical Research Communications242:545-551.
Nair, V. (2002) “HIV integrase as a target for antiviral chemotherapy,”Rev. Med. Virol.12:179-193.
Desai Manoj C.
Hong Allen Y.
Liu Hongtao
Vivian Randall W.
Xu Lianhong
Anderson Rebecca
Gilead Sciences, Inc.
Kutzenco Allan N.
Otton Alicia L
LandOfFree
Modulators of pharmacokinetic properties of therapeutics does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modulators of pharmacokinetic properties of therapeutics, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modulators of pharmacokinetic properties of therapeutics will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4294069